Literature DB >> 3264125

Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome.

P F Langlois1, M S Gawryl.   

Abstract

Extensive studies have been conducted to determine the pathogenesis of the adult respiratory distress syndrome (ARDS) by investigating the role of complement, a mediator of inflammation. Complement activation products have been detected in blood samples from patients during ARDS. However, the individual complement components that have been assessed only indicated generalized inflammation, and none could unequivocally discriminate the onset of this acute inflammatory lung injury. In this two-year prospective study of 87 septic patients, 22 of whom developed ARDS (25%), we determined complement activation by quantifying the terminal complement complex (TCC), C5b-9. The TCC is a stable complement by-product formed following activation of either the classical or alternative pathways. Our results show that plasma TCC concentrations increased an average of 110% (p = 0.002) two days prior to the onset of ARDS and also transiently increased an average of 45% (p = 0.01) immediately preceding its resolution. Furthermore, plasma TCC concentrations were a more sensitive measure of this acute inflammatory lung injury than levels of C3a desarginine, C4a desarginine, C5a desarginine, and total hemolytic complement activity. We conclude that a temporal association exists between accentuated formation of plasma TCC and the development and also resolution of septic ARDS. Therefore, we suggest that researchers include plasma TCC concentrations in clinical studies when they could use a potential early indicator for ARDS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264125     DOI: 10.1164/ajrccm/138.2.368

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement.

Authors:  B J Czermak; A B Lentsch; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

2.  Measurement of complement activation products in patients with chronic rheumatic diseases.

Authors:  G Auda; E R Holme; J E Davidson; A Zoma; J Veitch; K Whaley
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Chronological changes in the complement system in sepsis.

Authors:  H Nakae; S Endo; K Inada; M Yoshida
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

5.  Complement anaphylatoxin C3a and C5a formation in premature children with respiratory distress.

Authors:  A Enskog; A Bengtsson; J P Bengtson; M Heideman; S Andreasson; L Larsson
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

6.  Expression of integrin subunits alphav and beta3 in acute lung inflammation.

Authors:  Kyathanahalli S Janardhan; Greg D Appleyard; Baljit Singh
Journal:  Histochem Cell Biol       Date:  2004-04-28       Impact factor: 4.304

Review 7.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Soluble complex of complement increases hydraulic conductivity in single microvessels of rat lung.

Authors:  S Ishikawa; H Tsukada; J Bhattacharya
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  C5L2, the Second C5a Anaphylatoxin Receptor, Suppresses LPS-Induced Acute Lung Injury.

Authors:  Ruobing Wang; Bao Lu; Craig Gerard; Norma P Gerard
Journal:  Am J Respir Cell Mol Biol       Date:  2016-11       Impact factor: 6.914

10.  Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).

Authors:  T E Mollnes; H Redl; K Høgåsen; A Bengtsson; P Garred; L Speilberg; T Lea; M Oppermann; O Götze; G Schlag
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.